Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 16/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 0.98 |
| ▸ | HTR2C | P28335 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573920 | 0.99 | HTR2A (1.00) | HTR2ASLC6A2HTR6HTR2CHTR2B | |
| SCHEMBL3566822 | 0.99 | HTR2A (1.00) | HTR2ASLC6A2HTR6HTR2CHTR2B | |
| SCHEMBL3571706 | 0.92 | SLC6A2 (0.85) | HTR2ASLC6A2HTR6HTR2CHTR2B | |
| SCHEMBL3574301 | 0.92 | SLC6A2 (0.85) | HTR2ASLC6A2HTR6HTR2CHTR2B | |
| SCHEMBL3565057 | 0.92 | SLC6A2 (1.00) | HTR2ASLC6A2HTR6HTR2CKCNH2 | |
| SCHEMBL3568677 | 0.91 | SLC6A2 (0.83) | HTR2ASLC6A2HTR6HTR2CKCNH2 | |
| SCHEMBL3567790 | 0.89 | SLC6A2 (0.80) | HTR2ASLC6A2HTR6HTR2CHTR2B | |
| SCHEMBL3569728 | 0.88 | SLC6A2 (0.80) | HTR2ASLC6A2HTR6HTR2CHTR2B | |
| SCHEMBL3576275 | 0.88 | SLC6A2 (1.00) | HTR2ASLC6A2HTR6HTR2CKCNH2 | |
| SCHEMBL3577025 | 0.83 | SLC6A2 (0.96) | HTR2ASLC6A2HTR6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645752-B2 | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors | WYETH LLC (US) | 2010-01-12 | — | — | US | claimed |
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| US-7645752-B2 | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors | WYETH LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | HTR5A, HTR2C, HTR2A | HTR2A 3/4885SLC6A2 20/4885HTR6 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.